What are the specificities in France in terms of regulatory affairs?

In France, the pharmaceutical industry is closely monitored by ANSM (Agence nationale de sécurité du médicament et des produits de santé – National Agency for Medicines and Health Products Safety) that oversee pharmaceutical surveillance.


In addition to the European regulation this surveillance is carried out on the basis of French national legislation that defines which information must be provided to government Agencies, who are in charge of authorizing the marketing of drugs.


Consequently, understanding French local regulatory requirements is crucial for the success of a biopharmaceutical company planning to launch medicinal products in France or with an existing French organization.


The Public Health Code and the Social Security Code contain most of the legislation and decrees pertaining to medical and health products. The EU’s rules drive the national guidelines.


Regulatory authorities

Public agencies, under the authority of the Health Ministry, oversee monitoring and regulating health products, including:


  • Medical products
  • Cosmetics
  • Food supplements

The National Agency for Medicines and Health Products Safety (Agence nationale de sécurité du médicament et des produits de santé)

regulates human health products. 




The ANSM collaborates with:


  • National Agency for Food, Environmental and Occupational Health and Safety (Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail).
  • National Authority for Health (Haute Autorité de Santé) – HAS.
  • Economic Committee for Health Products (Comité économique des produits de santé) – CEP



  • Monitors clinical research taking place in France.
  • Monitors manufacturing, distribution, importation, exportation, advertisement and sale of health products (drug and medical device) and authorizes companies and their facilities to carry out these operations.
  • Manage Marketing authorizations approval and registrations of medical products
  • Monitors the safety of health products (drug & medical device) through pharmacovigilance

What is the role of the French Regulatory Affairs Department?

The Regulatory affairs (known in France as “affaires réglementaires”) team for a company in France will have a key role to play, thanks to its knowledge and expertise in a continuously and fast evolving regulatory environment. Regulatory Affairs are responsible of local regulatory compliance with French regulations and procedures.


In this context, it must be able to answer questions from French institutions on specific issues related to authorizations or on the socio-economic impact of a medicine, for example.


In addition to its expertise in regulatory affairs, the department will also be involved in external relations with French stakeholders (political representatives, members of academic and professional associations).


The French Regulatory Affairs team must therefore meet multiple expectations:


  • An expert assessment on the quality of the regulatory dossier
  • An understanding of legislation and practices implemented in France and Europe 
  • Capacity to anticipate on future changes that may be proposed by various stakeholders (authorities or industry), such as reference texts on pharmaceuticals, medical devices.
Regulatory affairs consulting in France

The Regulatory Affairs Department will need to rely on specific skills and training to have the ability to assume responsibility

and manage regulatory processes.


To meet these expectations, BlueReg offers valuable and unique specificities:

  • Regulatory Affairs experts with experience in various departments of the pharmaceutical industry:


BlueReg has over 50 regulatory affairs consultants who have worked within major French pharmaceutical companies for at least 10 years. 


This experience ensures a strong knowledge of the principles of pharmaceutical management, from development through to marketing authorization and commercialization.

  • A Regulatory Affairs Department with international experience:


BlueReg has been able to gain extensive expertise at a European level.


It is currently working for companies headquartered in Europe, North America and ROW. In this way, it has been able to bring its regulatory affairs consulting services in France in line with European and international standards.


This expertise makes BlueReg the partner of choice for companies who have a project to develop on both an international scale and in France.

Our regulatory affairs expertise for the French market

A dedicated team of highly qualified consultants and project manager providing services in France.


The team have:


  • Significant hands-on industry experience and broad expertise in national Regulatory Affairs, Quality Management and Pharmacovigilance.
  • Varied and flexible skills, ranging from strategic consulting to operational execution, as well as leading and project management.


The team works with many clients, from biotech start-ups to large pharma companies looking for local expertise or specific services for France.


The team have a highly successful track record of delivering all projects, from the simple to the complex. 



Our Latest Engagements


  • Review and submission of local promotional materials for pharmaceutical products and medical devices – ensuring it follows French local regulatory requirements (regulatory compliance)
  • Preparation of early access dossier (“accès précoce”) applications for an Orphan Drug
  • Handling of all local regulatory activities for a portfolio of pharmaceutical products
  • Preparation of MAA (Marketing Authorization Application) dossier for a new pharmaceutical product
  • Supporting a US company in obtaining an “Exploitant” status from the French National Agency for the Safety of Medicines and Health Products (ANSM) for their newly created affiliate in France. This included providing strategic advice to the client, setting up a specific Quality Management System (QMS) and preparing the “Exploitant” application filed to ANSM.

Regulatory Affairs France


Our regulatory affairs consulting services in France are designed to support clients during all the product development, registration and commercialization phases (launch, communications, lifecycle management). 


Please note that BlueReg is also able to provide regulatory solutions in all European countries. We support many biopharmaceutical companies from various location.


Interested to know more about our services, don’t hesitate to:


Contact us



Our experts

Associated News

The French system for preventing and managing shortages

The French regulation on the prevention and management of stock shortages of medicinal products is...

Learn more

New Appointment to our Leadership Team !

BlueReg Group is delighted to announce the appointment of Dominique Patrone as General Manager of PharmaBlue....

Learn more

Corinne Schmitz – Women for Future – Pharmaceutical Industry Expert

This week, “La Tribune” and its partner Bpifrance have decided to present Corinne Schmitz, CEO...

Learn more